Rising Antimicrobial Resistance Threatens Standard H. pylori Treatment Success, Drives Need for Personalized Therapies: Study

Standard antibiotic regimens for H. pylori—which affects over half the global population—are increasingly failing due to bacterial mutations, protective biofilms, and poor mucosal drug absorption. To address this clinical gap, Saha and colleagues from the Manipal Academy of Higher Education reviewed global epidemiology, regional resistance patterns, and emerging therapies to guide personalized eradication strategies.

Therefore, the narrative review analyzed global literature from 2001 to 2025 to evaluate H. pylori demographics, regional guidelines, and emerging treatments. Excluding small and non-clinical studies, the primary endpoint mapped geographic antimicrobial resistance patterns, while the secondary endpoint assessed the efficacy of novel, localized drug delivery systems.

Key Clinical Findings of the Review Includes:

• Geographic Resistance Variability: Researchers highlighted profound regional disparities, with clarithromycin resistance remaining relatively low in North America (15-20%) but soaring past 30-40% in urban Asia, rendering standard triple therapies largely ineffective.

• Epidemiological Disparities: Investigators noted an overall global prevalence of 44.3%, heavily skewed toward developing nations, peaking at roughly 70% in Africa compared to just 20-40% in Western Europe and North America.

• Superiority of Alternative Blockers: Authors revealed that vonoprazan-based triple therapies consistently achieved superior 88-92% eradication rates compared to the 73-76% success rates of traditional proton pump inhibitor (PPI) regimens.

• Efficacy of Novel Delivery Systems: Scientists reported that advanced formulations, such as polymeric nanoparticles and targeted gastro-retentive systems, can deliver up to a 15-fold increase in local bactericidal activity against multidrug-resistant strains.

The results suggest that successfully overcoming the complexities of multidrug-resistant H. pylori demands abandoning universal treatment plans in favor of a precision "test and treat" approach guided by susceptibility testing. Furthermore, incorporating advanced targeted drug carriers and non-antibiotic therapies holds immense potential to neutralize resistance and consistently achieve high eradication targets.

Thus, the review concludes clinicians may consider implementing regionally tailored eradication protocols guided by routine antimicrobial susceptibility testing, while cautiously integrating alternative therapies like vonoprazan or bismuth-quadruple regimens in high-resistance areas.

While the review highlights the limitation of poor surveillance quality and a lack of national registries in high-prevalence areas, gently exploring personalized site-specific drug delivery systems and establishing robust global resistance monitoring could further refine treatment success.

Reference

Saha, M., Shetty, S., Poojar, B., Musunuri, B., Narasimhaswamy, N., & Moorkoth, S. (2026). Helicobacter pylori eradication in the face of escalating anti-microbial resistance: Geographic heterogeneity and emerging treatment strategies. Indian Journal of Gastroenterology.